Working 55 hours or more per week associated with higher risk of stroke
the ONA take:
Working 55 hours or more per week is associated with a 33% increased risk for stroke and a 133% increased risk for developing coronary heart disease compared with working a standard 40-hour week, a large study published in the journal The Lancet has shown.
For the systematic review, researchers from University College London in London, UK, sought to examine the effects of longer workup hours on cardiovascular disease up to mid-2014. The analysis included 603,838 people from 3 continents that participated in 25 studies.
Researchers found that people who worked 55 hours or more per week had a 13% increased of incident coronary heart disease compared with those working 35 to 40 hours per week. When researchers only included 528,908 from 17 studies, there was 1.3 times greater risk of stroke in people working 55 or more hours a week compared with those working standard hours.
"Health professionals should be aware that working long hours is associated with a significantly increased risk of stroke, and perhaps also coronary heart disease," Mika Kivimäki, Professor of Epidemiology at University College London, UK, said.
Working 55 hours or more per week is associated with a 33% increased risk for stroke and a 133% increased risk for developing coronary heart disease .
- Prolonged Imatinib Therapy Improves Likelihood of Deeper Molecular Response
- Ruxolitinib Effective as Long-term Treatment Option for Polycythemia Vera
- Study Affirms Activity of Ibrutinib in Patients With R/R CLL With 17p Deletion
- Patients Receiving RT in APBI Facilities Despite Eligibility for Observation
- ASCO, ASTRO Issue Guideline Update for Postmastectomy RT
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- Longer Maintenance Therapy Duration May Improve Survival in Myeloma
- HRQoL Better Maintained With Pembrolizumab in Ipilimumab-refractory Melanoma
- Economic Evaluation of Obinutuzumab in Combination With Chlorambucil in First-line Treatment of Patients With Chronic Lymphocytic Leukemia in Spain
- MRD Assessment Improves PFS Prediction in Patients With CLL
- Cancer Patients Have Unrealistic Hopes When Entering Clinical Trials
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|